Form 4: Director Habib J. Dable Receives Tyra Biosciences Options

Director Habib J. Dable was granted 44,400 stock options in Tyra Biosciences, Inc. as part of a standard equity incentive.

Summary

• Habib J. Dable, a Director at Tyra Biosciences, Inc., was granted 44,400 stock options on April 16, 2026.
• The options have an exercise price of $35.12 per share.
• The options are set to expire on April 15, 2036.
• Vesting occurs monthly over a 36-month period starting from the grant date, contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the granted options.
• Dependence on the company's ability to maintain continuous service of key personnel to achieve full vesting.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on the equity compensation of a director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure leadership remains incentivized toward long-term clinical and commercial milestones.

Comparison to Industry Standards

• The use of 36-month monthly vesting schedules is consistent with standard corporate governance practices for board members in the life sciences industry.

Stakeholder Impact

• Minor dilution impact on existing shareholders upon future exercise of options.

Next Steps

• Vesting of options on a monthly basis starting May 2026.

Key Dates

Keywords

Tyra Biosciences, TYRA, Form 4, Insider Trading, Stock Options, Director Compensation